The microbiological outcomes of culture-negative blood specimens using 16S rRNA broad-range PCR sequencing: a retrospective study in a Canadian province from 2018 to 2022

Broad-range 16S rRNA PCR and sequencing of 1,183 blood specimens from 853 unique patients yielded an interpretable sequence and bacterial identification in 29%, 16S rRNA amplification with uninterpretable sequences in 53%, and no amplification in 18%. This study highlights the potential utility of t...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical microbiology Vol. 62; no. 3; p. e0151823
Main Authors Lieu, Anthony, Harrison, Luke B, Harel, Josée, Lawandi, Alexander, Cheng, Matthew P, Domingo, Marc-Christian
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 13.03.2024
Subjects
Bacteriology
Canada
Clinical Microbiology
DNA, Bacterial - genetics
Humans
Polymerase Chain Reaction - methods
Retrospective Studies
RNA, Ribosomal, 16S - genetics
Sequence Analysis, DNA
Canada
16S rRNA gene sequencing
broad-range bacterial sequencing
blood specimens
culture-negative infection
Online AccessGet full text

Cover

More Information
Summary:Broad-range 16S rRNA PCR and sequencing of 1,183 blood specimens from 853 unique patients yielded an interpretable sequence and bacterial identification in 29%, 16S rRNA amplification with uninterpretable sequences in 53%, and no amplification in 18%. This study highlights the potential utility of this technique in identifying fastidious gram-negative and anaerobic bacteria but the frequent recovery of environmental and contaminant organisms argues for its judicious use. The existing literature focuses on its performance compared to blood cultures in patients with sepsis, leaving a gap in the literature regarding other blood specimens in suspected infectious syndrome across the severity spectrum. We aimed to characterize its microbiological outcomes and provide insight into its potential clinical utility.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Unrelated to this study, Dr. Cheng reports grants from the Canadian Institutes of Health Research during the conduct of the study and is supported by the Fonds de Recherche du Québec—Santé. He reports personal fees from GEn1E Lifesciences and from nomic bio as a member of the scientific advisory board, as well as honoraria from AstraZeneca, Takeda, Merck, and Pfizer. He reports research support from Cidara Therapeutics, from Scynexis, Inc., and from Amplyx Pharmaceutics during the conduct of the study but outside the submitted work. Dr. Cheng is the co-founder of Kanvas Biosciences, Inc., and owns equity in the company. Dr. Cheng has pending patents, including (i) Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling, (ii) Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending, and (iii) Rapid identification of antimicrobial resistance and other microbial phenotypes using highly multiplexed fluorescence in situ hybridization.
ISSN:0095-1137
1098-660X
1098-660X
DOI:10.1128/jcm.01518-23